Open AccessHIF ‐2α regulates non‐canonical glutamine metabolism via activation of PI 3K/ mTORC 2 pathway in human pancreatic ductal adenocarcinoma
Author(s) -
Li Wenzhu,
Chen Changhao,
Zhao Xiaohui,
Ye Huilin,
Zhao Yue,
Fu Zhiqiang,
Pan Wenwei,
Zheng Shangyou,
Wei Lusheng,
g Tianwen,
Li Zhihua,
Chen Rufu
Publication year - 2017
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.13202
Subject(s) - cancer research , gene silencing , pancreatic cancer , metastasis , pi3k/akt/mtor pathway , adenocarcinoma , medicine , glutamine , biology , cancer , signal transduction , microbiology and biotechnology , biochemistry , amino acid , gene
Hypoxia‐inducible factor‐2α ( HIF ‐2α) plays an important role in increasing cancer progression and distant metastasis in a variety of tumour types. We aimed to investigate its biological function and clinical significance in human pancreatic ductal adenocarcinoma ( PDAC ). A total of 283 paired PDAC tissues and adjacent normal tissues were collected from patients who underwent surgery or biopsy at Sun Yat‐sen Memorial Hospital between February 2004 and October 2016. In this study, we noted that HIF ‐2α expression was significantly up‐regulated in PDAC , positively associated with disease stage, lymph‐node metastasis and patient survival, and identified as an independent prognostic factor of PDAC patients. We demonstrated that HIF ‐2α silencing could reduce proliferation, migration and invasion of PDAC cells in vitro . The similar effect on growth was demonstrated in vivo . Furthermore, we noted that knock‐down of HIF ‐2α significantly decreased the expression of glutamate oxaloacetate transaminase 1 ( GOT 1). Importantly, we confirmed that the PI 3K/ mTORC 2 pathway promoted GOT 1 expression by targeting HIF ‐2α. Our study validated HIF ‐2α was an important factor in PDAC progression and poor prognosis and may promote non‐canonical glutamine metabolism via activation of PI 3K/ mTORC 2 pathway. Targeting HIF ‐2α represents a novel prognostic biomarker and therapeutic target for patients with PDAC.